Trial Search Results
Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome
The investigators are testing treatment with low-dose naltrexone (LDN) for symptom relief of complex regional pain syndrome (CRPS). Study participants will be randomly assigned to receive either LDN or placebo for a period of several weeks. During this period participants will be asked to come to several visits, which will include sensory testing, physical assessments, and questionnaires.
Stanford is currently accepting patients for this trial.
- Drug: LDN
- Drug: Placebo
- Upper and/or lower extremity CRPS
- On stable treatment for 3 months
- CRPS for at least 1 year
- Meet the Budapest criteria for CRPS at time of the study.
- Any known allergy to naltrexone or naloxone
- Use of prescription opioid analgesics or illegal opioid use
- Current of planned pregnancy.
Ages Eligible for Study
18 Years - 65 Years
Genders Eligible for Study